Participant Flow:



Baseline Characteristics:

Table 1. Baseline characteristics of the patients
--

	Diosmin group	Control group
	n=150	n=150
Male (n, %)	76, 50.7%	73, 48.7%
Age (years, mean±SD)	41±6.5	42±7.4
Treatment course (months, mean±SD)	4±1.4	4±1.5
Duration of pain (n, %)		
<3 months	45, 30.0%	47, 31.3%
3-12months	62, 41.3%	65, 65%
13-36 months	29, 19.3%	27, 18.0%
>36 months	14, 9.3%	11, 7.3%
Pretreatment with opioids (n, %)		
None	118, 78.5%	114, 76.0%
<60 morphine equivalents/day	21, 14.0%	23, 15.3%
≥60 morphine equivalents/day	11, 7.3%	13, 8.7%
Current smoker (n,%)	21, 14.0%	23, 15.3%
Obesity (n,%)	23, 15.3%	25, 16.7%
Level of lesion (culprit nerve root, n, %)		
L2-3/ L3	9, 6.0%	11, 7.3%
L3-4/ L4	13, 8.7%	15, 10.0%
L4-5/ L5	99, 66.0%	101, 67.3%
L5-S1/ S1	29, 19.3%	23, 15.3%
Baseline pain scores (mean \pm SD)		
VAS	8.9±1.1	9.1±0.4
RM-Q	17.2±2.7	17.4±2.3
NRS	78.2±6.5	77.5±2.6
Number of patients with serious pain given diclofenac (n, %)	6, 3.9%	5, 3.3%

VAS: Visual analogue scale; NRS: Numerical rating scale; RM-Q: Roland-Morris questionnaire

Outcome Measures:

Outcome	Diosmin			Control		
Outcome	Pre-treatment	2 weeks	8 weeks	Pre-treatment	2 weeks	8 weeks
RM-Q	17.2±2.7	11.8±3.1	9.1±2.3	17.4±2.3	11.3±2.7	8.1±3.2
NRS	78.2±6.5	56.7±10.1	34.3±.3.4	77.5±2.6	54.3±.3.7	32.3±.3.5
VAS	8.9±1.1	5.2±0.4	3.6±1.2	9.1±0.4	5.5±1.3	3.4±0.5

Table 2. Comparisons of RM-Q, NRS, and VAS scores between pre- and post-treatment

VAS: Visual analogue scale; NRS: Numerical rating scale; RM-Q: Roland-Morris questionnaire

Table 3. Patient satisfaction and other medication usage at 24 months after randomization	Table 3. Patient satisfaction and	other medication usage at 24	months after randomization
--	-----------------------------------	------------------------------	----------------------------

	Diosmin	Control
Satisfaction of patients (n, %)		
Completely satisfied	76, 50.7%	77, 51.3%
Satisfied	51, 34.0%	49, 32.7%
Unsatisfied	23, 15.3%	24, 16.0%
Other medication usage (n, %)	46, 30.7%	43, 28.7%
Nonsteroidal anti-inflammatory drugs (n, %)	41, 27.3%	39, 72.7%
Opioid medications (n, %)	33, 22.0%	36, 24.0%

Adverse Events:

Table 4. Adverse events

	Diosmin	Control
Serious (n, %)	0, 0%	0, 0%
Non-serious (n, %)	0,.0%	5, 3.33%
Mild nausea	0, 0%	5, 3.33%
Total	0, 0%	5, 3.33%